PMID- 14606102
OWN - NLM
STAT- MEDLINE
DCOM- 20031219
LR  - 20190430
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 9
IP  - 11
DP  - 2003 Nov
TI  - Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and 
      nocturnal alkaline amplitude.
PG  - 2583-6
AB  - AIM: To study the effect of rabeprazole (RAB) on nocturnal acid breakthrough 
      (NAB) and nocturnal alkaline amplitude (NAKA) and to compare it with omeprazole 
      (OME) and pantoprazole (PAN). METHODS: By an open comparative study, forty 
      patients with active peptic ulcer were randomly assigned to receive one of the 
      three PPIs (proton pump inhibitor) with a single oral dose. They were divided 
      into RAB group (10 mg), OME group (20 mg) and PAN group (40 mg). Twenty healthy 
      volunteers were enrolled to the control group (without taking any drug). 
      Intragastric pH monitoring was then performed 1 hour before and 24 hours after 
      the dose was given. RESULTS: No clinically undesirable signs and symptoms 
      possibly attributed to the administration of RAB or OME and PAN were recognizable 
      throughout the study period. All subjects completed the study according to the 
      protocol. All data were processed by a computer using the Student t test or t' 
      test followed by an analysis of covariance. P<0.05 was considered to have 
      statistical significance. The intragastric pH of NAB was significantly higher in 
      RAB group (1.84+/-0.55) than in either OME group (1.15+/-0.31) or PAN group 
      (1.10+/-0.30) (both P<0.01). RAB produced a longer sustaining time (4.65+/-1.22 
      h) on NAKA than OME (3.22+/-1.89 h) (P<0.05), PAN (3.15+/-1.92 h) (P<0.05), and 
      the sustaining time of NAKA in RAB group was longer than that in the healthy 
      control group (P<0.01) too. In addition, RAB produced a much higher pH on NAKA 
      (6.41+/-0.45) in comparison with PAN (6.01+/-0.92) (P<0.05). CONCLUSION: A single 
      oral dose of 10 mg RAB may increase the pH of NAB and shorten the sustaining time 
      of NAB, and it may increase the pH of NAKA as well as prolong the sustaining time 
      of NAKA.
FAU - Luo, Jin-Yan
AU  - Luo JY
AD  - Department of Gastroenterology, The Second Hospital of Xi'an Jiaotong University, 
      Xi'an 710004, Shanxi Province, China. ljy18272@163.com
FAU - Niu, Chun-Yan
AU  - Niu CY
FAU - Wang, Xue-Qin
AU  - Wang XQ
FAU - Zhu, You-Ling
AU  - Zhu YL
FAU - Gong, Jun
AU  - Gong J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Alkalies)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Sulfoxides)
RN  - 32828355LL (Rabeprazole)
RN  - D8TST4O562 (Pantoprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Administration, Oral
MH  - Adult
MH  - *Alkalies
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Benzimidazoles/*administration & dosage
MH  - Circadian Rhythm
MH  - Female
MH  - *Gastric Acid
MH  - Humans
MH  - Hydrogen-Ion Concentration/drug effects
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/administration & dosage
MH  - Pantoprazole
MH  - Peptic Ulcer/*drug therapy
MH  - Rabeprazole
MH  - Sulfoxides/administration & dosage
PMC - PMC4656546
EDAT- 2003/11/08 05:00
MHDA- 2003/12/20 05:00
PMCR- 2003/11/15
CRDT- 2003/11/08 05:00
PHST- 2003/11/08 05:00 [pubmed]
PHST- 2003/12/20 05:00 [medline]
PHST- 2003/11/08 05:00 [entrez]
PHST- 2003/11/15 00:00 [pmc-release]
AID - 10.3748/wjg.v9.i11.2583 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2003 Nov;9(11):2583-6. doi: 10.3748/wjg.v9.i11.2583.